Current Stock Developments and Forecast
In May 2025, the stock price of BioNTech is forecasted to be around 90 to 102 US dollars, showing an upward trend throughout the year. Stock predictions for the coming months indicate positive developments: In September 2025, a price of 105 to 116 US dollars is expected, and in November, it could rise to about 115 US dollars. This suggests a recovery and potential upward trend.
Analysts’ Opinions
The majority of analysts rate the stock positively. Out of a total of 21 available analyses, 17 recommend a “Buy” or “Strong Buy,” with no sell recommendations present. The average price target for the next year is approximately 135 US dollars, which, compared to the current price of about 83 Euros (approximately corresponding to the mentioned range of about 90-100 dollars), might indicate an undervaluation.
Challenges and Opportunities
BioNTech faces new challenges following the pandemic phase, particularly in advancing mRNA-based therapies beyond the Corona vaccine. The company continues to invest heavily in innovative medical fields such as cancer immunotherapies and other vaccines, which offers long-term growth potential.
Conclusion
The combination of a stable technical chart situation with rising peaks and a strong fundamental basis due to new medical developments suggests that a rebound for the BioNTech stock is realistic. This creates interesting opportunities for investors in light of a positive market environment and optimistic analyst assessments.